Adam J. Townsend
Net Worth
Last updated:
What is Adam J. Townsend net worth?
The estimated net worth of Mr. Adam J. Townsend is at least $10,792,474 as of 12 Feb 2024. He owns shares worth $2,461,099 as insider, has earned $6,359,505 from insider trading and has received compensation worth at least $1,971,870 in Apellis Pharmaceuticals, Inc..
What is the salary of Adam J. Townsend?
Mr. Adam J. Townsend salary is $657,290 per year as Chief Commercial Officer in Apellis Pharmaceuticals, Inc..
How old is Adam J. Townsend?
Mr. Adam J. Townsend is 48 years old, born in 1977.
What stocks does Adam J. Townsend currently own?
As insider, Mr. Adam J. Townsend owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Chief Commercial Officer | 92,453 | $26.62 | $2,461,099 |
What does Apellis Pharmaceuticals, Inc. do?
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Adam J. Townsend insider trading
Apellis Pharmaceuticals, Inc.
Mr. Adam J. Townsend has made 18 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,148 units of APLS stock worth $77,797 on 12 Feb 2024.
The largest trade he's ever made was exercising 12,500 units of APLS stock on 8 Aug 2022. As of 12 Feb 2024 he still owns at least 92,453 units of APLS stock.
Apellis Pharmaceuticals key executives
Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Cedric Francois (53) Co-Founder, Pres, Chief Executive Officer & Director
- Dr. Pascal Deschatelets Ph.D. (55) Co-Founder & Chief Scientific Officer
- Mr. Adam J. Townsend (48) Chief Commercial Officer
- Mr. Alec Machiels J.D., MBA (52) Co-Founder & Independent Director
- Mr. Timothy E. Sullivan (54) Chief Financial Officer